Surgical therapy for early hepatocellular carcinoma in the modern era

A 10-Year SEER-medicare analysis

Hari Nathan, Omar Hyder, Skye C. Mayo, Kenzo Hirose, Christopher L. Wolfgang, Michael A. Choti, Timothy M. Pawlik

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

OBJECTIVE:: We sought to quantify the use of and analyze factors predictive of receipt of surgical therapy for early hepatocellular carcinoma (HCC). BACKGROUND:: The incidence of HCC is increasing, and the options for surgical therapy for early HCC have expanded, but the use of surgical therapy for early HCC has not been examined in a modern cohort. METHODS:: A retrospective cohort study was performed using data from the 1998-2007 Surveillance, Epidemiology, and End Results-Medicare linked database. Data were analyzed for patients 66 years of age and older with early HCC (tumors ≤5 cm without metastatic disease, nodal metastasis, extrahepatic extension, or major vascular invasion). Both Surveillance, Epidemiology, and End Results and Medicare data were used to ascertain receipt of therapy as well as comorbidity burden and other patient and hospital variables. Multivariable logistic regression models were used to analyze factors associated with receipt of therapy. RESULTS:: Our selection criteria identified 1745 patients for this study. Most patients had tumors between 2 and 5 cm in size (n = 1440, 83%). Solitary tumors (n = 1121, 64%) were more common than multiple tumors (n = 624, 36%). A total of 820 patients (47%) with early HCC received no surgical therapy. Among 741 patients with solitary, unilobar tumors and microscopic confirmation of HCC, 246 (33%) received no surgical therapy. Of 535 patients with no liver-related comorbidities, 273 (51%) did not receive surgical therapy. In multivariable analysis, patient age, income, tumor factors, liver-related comorbidities, and hospital factors were associated with receipt of surgical therapy. CONCLUSIONS:: Although some patients with early HCC may not be candidates for surgical therapy, these data suggest that there is a significant missed opportunity to improve survival of patients with early HCC through the use of surgical therapy.

Original languageEnglish (US)
Pages (from-to)1022-1027
Number of pages6
JournalAnnals of Surgery
Volume258
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

antineoplaston A10
Medicare
Hepatocellular Carcinoma
Therapeutics
Comorbidity
Neoplasms
Statistical Factor Analysis
Epidemiology
Logistic Models
Liver
Patient Selection
Blood Vessels
Cohort Studies
Retrospective Studies
Databases
Neoplasm Metastasis

Keywords

  • hepatocellular carcinoma
  • SEER-Medicare
  • surgery
  • therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Surgical therapy for early hepatocellular carcinoma in the modern era : A 10-Year SEER-medicare analysis. / Nathan, Hari; Hyder, Omar; Mayo, Skye C.; Hirose, Kenzo; Wolfgang, Christopher L.; Choti, Michael A.; Pawlik, Timothy M.

In: Annals of Surgery, Vol. 258, No. 6, 12.2013, p. 1022-1027.

Research output: Contribution to journalArticle

Nathan, Hari ; Hyder, Omar ; Mayo, Skye C. ; Hirose, Kenzo ; Wolfgang, Christopher L. ; Choti, Michael A. ; Pawlik, Timothy M. / Surgical therapy for early hepatocellular carcinoma in the modern era : A 10-Year SEER-medicare analysis. In: Annals of Surgery. 2013 ; Vol. 258, No. 6. pp. 1022-1027.
@article{44ea62cec7c540f68ea1eabd849c647a,
title = "Surgical therapy for early hepatocellular carcinoma in the modern era: A 10-Year SEER-medicare analysis",
abstract = "OBJECTIVE:: We sought to quantify the use of and analyze factors predictive of receipt of surgical therapy for early hepatocellular carcinoma (HCC). BACKGROUND:: The incidence of HCC is increasing, and the options for surgical therapy for early HCC have expanded, but the use of surgical therapy for early HCC has not been examined in a modern cohort. METHODS:: A retrospective cohort study was performed using data from the 1998-2007 Surveillance, Epidemiology, and End Results-Medicare linked database. Data were analyzed for patients 66 years of age and older with early HCC (tumors ≤5 cm without metastatic disease, nodal metastasis, extrahepatic extension, or major vascular invasion). Both Surveillance, Epidemiology, and End Results and Medicare data were used to ascertain receipt of therapy as well as comorbidity burden and other patient and hospital variables. Multivariable logistic regression models were used to analyze factors associated with receipt of therapy. RESULTS:: Our selection criteria identified 1745 patients for this study. Most patients had tumors between 2 and 5 cm in size (n = 1440, 83{\%}). Solitary tumors (n = 1121, 64{\%}) were more common than multiple tumors (n = 624, 36{\%}). A total of 820 patients (47{\%}) with early HCC received no surgical therapy. Among 741 patients with solitary, unilobar tumors and microscopic confirmation of HCC, 246 (33{\%}) received no surgical therapy. Of 535 patients with no liver-related comorbidities, 273 (51{\%}) did not receive surgical therapy. In multivariable analysis, patient age, income, tumor factors, liver-related comorbidities, and hospital factors were associated with receipt of surgical therapy. CONCLUSIONS:: Although some patients with early HCC may not be candidates for surgical therapy, these data suggest that there is a significant missed opportunity to improve survival of patients with early HCC through the use of surgical therapy.",
keywords = "hepatocellular carcinoma, SEER-Medicare, surgery, therapy",
author = "Hari Nathan and Omar Hyder and Mayo, {Skye C.} and Kenzo Hirose and Wolfgang, {Christopher L.} and Choti, {Michael A.} and Pawlik, {Timothy M.}",
year = "2013",
month = "12",
doi = "10.1097/SLA.0b013e31827da749",
language = "English (US)",
volume = "258",
pages = "1022--1027",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Surgical therapy for early hepatocellular carcinoma in the modern era

T2 - A 10-Year SEER-medicare analysis

AU - Nathan, Hari

AU - Hyder, Omar

AU - Mayo, Skye C.

AU - Hirose, Kenzo

AU - Wolfgang, Christopher L.

AU - Choti, Michael A.

AU - Pawlik, Timothy M.

PY - 2013/12

Y1 - 2013/12

N2 - OBJECTIVE:: We sought to quantify the use of and analyze factors predictive of receipt of surgical therapy for early hepatocellular carcinoma (HCC). BACKGROUND:: The incidence of HCC is increasing, and the options for surgical therapy for early HCC have expanded, but the use of surgical therapy for early HCC has not been examined in a modern cohort. METHODS:: A retrospective cohort study was performed using data from the 1998-2007 Surveillance, Epidemiology, and End Results-Medicare linked database. Data were analyzed for patients 66 years of age and older with early HCC (tumors ≤5 cm without metastatic disease, nodal metastasis, extrahepatic extension, or major vascular invasion). Both Surveillance, Epidemiology, and End Results and Medicare data were used to ascertain receipt of therapy as well as comorbidity burden and other patient and hospital variables. Multivariable logistic regression models were used to analyze factors associated with receipt of therapy. RESULTS:: Our selection criteria identified 1745 patients for this study. Most patients had tumors between 2 and 5 cm in size (n = 1440, 83%). Solitary tumors (n = 1121, 64%) were more common than multiple tumors (n = 624, 36%). A total of 820 patients (47%) with early HCC received no surgical therapy. Among 741 patients with solitary, unilobar tumors and microscopic confirmation of HCC, 246 (33%) received no surgical therapy. Of 535 patients with no liver-related comorbidities, 273 (51%) did not receive surgical therapy. In multivariable analysis, patient age, income, tumor factors, liver-related comorbidities, and hospital factors were associated with receipt of surgical therapy. CONCLUSIONS:: Although some patients with early HCC may not be candidates for surgical therapy, these data suggest that there is a significant missed opportunity to improve survival of patients with early HCC through the use of surgical therapy.

AB - OBJECTIVE:: We sought to quantify the use of and analyze factors predictive of receipt of surgical therapy for early hepatocellular carcinoma (HCC). BACKGROUND:: The incidence of HCC is increasing, and the options for surgical therapy for early HCC have expanded, but the use of surgical therapy for early HCC has not been examined in a modern cohort. METHODS:: A retrospective cohort study was performed using data from the 1998-2007 Surveillance, Epidemiology, and End Results-Medicare linked database. Data were analyzed for patients 66 years of age and older with early HCC (tumors ≤5 cm without metastatic disease, nodal metastasis, extrahepatic extension, or major vascular invasion). Both Surveillance, Epidemiology, and End Results and Medicare data were used to ascertain receipt of therapy as well as comorbidity burden and other patient and hospital variables. Multivariable logistic regression models were used to analyze factors associated with receipt of therapy. RESULTS:: Our selection criteria identified 1745 patients for this study. Most patients had tumors between 2 and 5 cm in size (n = 1440, 83%). Solitary tumors (n = 1121, 64%) were more common than multiple tumors (n = 624, 36%). A total of 820 patients (47%) with early HCC received no surgical therapy. Among 741 patients with solitary, unilobar tumors and microscopic confirmation of HCC, 246 (33%) received no surgical therapy. Of 535 patients with no liver-related comorbidities, 273 (51%) did not receive surgical therapy. In multivariable analysis, patient age, income, tumor factors, liver-related comorbidities, and hospital factors were associated with receipt of surgical therapy. CONCLUSIONS:: Although some patients with early HCC may not be candidates for surgical therapy, these data suggest that there is a significant missed opportunity to improve survival of patients with early HCC through the use of surgical therapy.

KW - hepatocellular carcinoma

KW - SEER-Medicare

KW - surgery

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84888138358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888138358&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e31827da749

DO - 10.1097/SLA.0b013e31827da749

M3 - Article

VL - 258

SP - 1022

EP - 1027

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -